Compare APYX & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APYX | WHWK |
|---|---|---|
| Founded | 1982 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.0M | 95.2M |
| IPO Year | 1987 | N/A |
| Metric | APYX | WHWK |
|---|---|---|
| Price | $3.86 | $2.38 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | 120.9K | ★ 186.0K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $47,902,000.00 | $14,384,000.00 |
| Revenue This Year | $8.50 | N/A |
| Revenue Next Year | $7.18 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.76 | $1.39 |
| 52 Week High | $4.44 | $3.81 |
| Indicator | APYX | WHWK |
|---|---|---|
| Relative Strength Index (RSI) | 51.41 | 50.30 |
| Support Level | $3.92 | $2.10 |
| Resistance Level | $4.14 | $2.63 |
| Average True Range (ATR) | 0.19 | 0.17 |
| MACD | -0.05 | 0.02 |
| Stochastic Oscillator | 15.22 | 41.51 |
Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing, and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. Its product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons, and cosmetic physicians the ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminates unintended tissue trauma. It operates in two segments namely: Advanced Energy and Original Equipment Manufacturing (OEM). Its Advanced Energy segment derives the majority of its revenue.
Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.